IN8bio Crescita futura

Future criteri di controllo 0/6

Si prevede che IN8bio aumenterà gli utili e i ricavi rispettivamente del 14.6% e 92.7% all'anno, mentre si prevede che l'EPS crescerà del 38.9% all'anno.

Informazioni chiave

14.6%

Tasso di crescita degli utili

38.9%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.3%
Tasso di crescita dei ricavi	92.7%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	26 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:INAB - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	N/A	-31	-22	N/A	5
12/31/2025	N/A	-24	-10	N/A	5
12/31/2024	N/A	-29	-22	N/A	5
9/30/2024	N/A	-32	-25	-25	N/A
6/30/2024	N/A	-32	-25	-25	N/A
3/31/2024	N/A	-31	-24	-24	N/A
12/31/2023	N/A	-30	-24	-23	N/A
9/30/2023	N/A	-30	-28	-26	N/A
6/30/2023	N/A	-30	-30	-26	N/A
3/31/2023	N/A	-30	-31	-27	N/A
12/31/2022	N/A	-29	-28	-24	N/A
9/30/2022	N/A	-27	-21	-18	N/A
6/30/2022	N/A	-23	-20	-19	N/A
3/31/2022	N/A	-18	-16	-16	N/A
12/31/2021	N/A	-15	-14	-14	N/A
9/30/2021	N/A	-12	-13	-13	N/A
6/30/2021	N/A	-11	-9	-9	N/A
3/31/2021	N/A	-11	-8	-8	N/A
12/31/2020	N/A	-10	-7	-7	N/A
9/30/2020	N/A	-9	-7	-7	N/A
6/30/2020	N/A	-8	-6	-6	N/A
3/31/2020	N/A	-6	-6	-5	N/A
12/31/2019	N/A	-6	-5	-5	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che INAB rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che INAB rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che INAB rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che INAB non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che INAB non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di INAB è previsto essere elevato tra 3 anni

IN8bio Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 16% to US$11.00

Price target decreased to US$9.67

Recent updates

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio (NASDAQ:INAB) Will Have To Spend Its Cash Wisely

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024

In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc., Annual General Meeting, Jun 12, 2024

IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

New major risk - Financial position

IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP

New major risk - Shareholder dilution

Price target decreased by 16% to US$11.00

IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

IN8bio, Inc.’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting

IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Companies Like IN8bio (NASDAQ:INAB) Could Be Quite Risky

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting

IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme

IN8bio, Inc. Announces Positive Preclinical Data Underscoring the Potential of Its DeltEx Gamma-Delta T Cells to Target and Kill Ovarian Cancer

Is IN8bio (NASDAQ:INAB) In A Good Position To Invest In Growth?

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

In8bio Announces New Data At Ash Showing 100% of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of Inb-100

IN8bio Announces FDA Clearance to Initiate A Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

Price target decreased to US$9.67

High number of new and inexperienced directors

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

High number of new and inexperienced directors

Here's Why We're Watching IN8bio's (NASDAQ:INAB) Cash Burn Situation

High number of new and inexperienced directors

IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board

IN8bio gains 53% as H.C. Wainwright initiates with Buy

Independent Director recently bought US$200k worth of stock

IN8bio raises additional funds from underwriter of stock offering

IN8bio prices $10.25M stock offering

IN8bio, Inc. Provides Clinical Update from Ongoing Phase 1 Trial of INB-100

IN8bio, Inc. Appoints Kenneth R. Lamontagne as Senior Vice President, Business Development

IN8bio, Inc. Announces Positive Glioblastoma Multiforme (Gbm) Clinical Updates from the INB-200 Phase 1 Trial Presented At Asco 2022

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

IN8bio, Inc., Annual General Meeting, Jun 01, 2022

IN8bio, Inc. Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100

IN8bio (NASDAQ:INAB) Is In A Good Position To Deliver On Growth Plans

IN8bio, Inc. Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

In8bio Provides Update from the Ongoing Phase 1 Clinical Trial of Its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

IN8bio, Inc. Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

Director recently bought US$1.0m worth of stock

IPO Update: IN8bio Aims For Downsized IPO

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita